Business Context and Reporting Period
This Form 8-K filing by Global Medical REIT Inc. (GMRE), dated November 13, 2025, reports the Company's financial results for the third quarter and nine months ended September 30, 2025. The Company operates a portfolio of medical real estate, including outpatient medical buildings, inpatient rehabilitation facilities, and hospitals.
Key Financial Metrics
Profitability and Earnings
- Q3 2025 Net Loss: Approximately $6.0 million ($0.45 per diluted share) attributable to common stockholders, compared to net income of $1.8 million ($0.14 per diluted share) in Q3 2024.
- YTD 2025 Net Loss: Approximately $4.7 million ($0.35 per diluted share) for the nine months ended September 30, 2025, compared to a net loss of $0.6 million ($0.04 per diluted share) in the prior year period.
- EBITDAre (Q3 2025): $24.2 million.
- Adjusted EBITDAre (Q3 2025): $25.7 million.
Operating Performance
- Same-Store Cash NOI Growth: 2.7% year-over-year for Q3 2025.
- Same-Store Cash NOI (Q3 2025): $25.3 million.
- Portfolio Occupancy: 95.2% as of September 30, 2025.
- Leasable Square Footage: Approximately 5.2 million square feet.
- Annualized Base Rent: Approximately $118.4 million.
- Weighted Average Lease Term: 5.3 years.
Debt and Liquidity
- Total Gross Debt: $712.9 million.
- Net Debt: $705.7 million (Gross debt less unrestricted cash of $7.1 million).
- Preferred Stock: $74.6 million.
- Leverage Ratios (Q3 2025): Net Debt / Annualized Adjusted EBITDAre is 6.9x; Net Debt + Preferred / Annualized Adjusted EBITDAre is 7.6x.
Material Changes vs. Prior Period
- Net Income to Loss: The Company shifted from a net income of $3.4 million in Q3 2024 to a net loss of $5.1 million in Q3 2025 (GAAP basis).
- Impairment Charges: A significant impairment of investment property of $6.3 million was recorded in Q3 2025, compared to none in the prior year.
- Debt Levels: Total Gross Debt increased from $634.3 million in Q3 2024 to $712.9 million in Q3 2025.
- Leverage Increase: The Net Debt to Annualized Adjusted EBITDAre ratio increased from 6.5x in Q3 2024 to 6.9x in Q3 2025.
- Gain on Sale: Gain on sale of investment properties decreased from $1.8 million in Q3 2024 to $0.3 million in Q3 2025.
Outlook, Risks, and Unusual Items
- Unusual Items: The Q3 2025 results were impacted by a $6.3 million impairment charge on investment property and $0.2 million in reverse stock split expenses.
- Portfolio Composition: The portfolio is 72% outpatient medical buildings, 25% inpatient rehabilitation/hospitals, and 3% other medical real estate.
- Lease Expirations: Approximately 11.7% of leased square footage expires in 2026, with 14.4% expiring in 2029 and 15.8% in 2035 or later.
- Management Commentary: Management highlights Same-Store Cash NOI growth of 2.7% as a key indicator of core operating performance, despite the GAAP net loss driven by non-cash impairments and interest expenses.
Investor Verification Checklist
- Verify the specific nature and recoverability of the $6.3 million investment property impairment charge.
- Confirm the details of the debt increase from $634.3 million to $712.9 million and the associated interest rate environment.
- Review the lease renewal pipeline for the 11.7% of square footage expiring in 2026 to assess future rental rate risks.
- Assess the impact of the reverse stock split expense on future capital structure decisions.
- Validate the 2.7% same-store cash NOI growth against broader market trends for medical real estate.